Newly diagnosed multiple myeloma patients with poor response to standard therapy

In this study, we analyzed transcriptome sequencing data to compare NDMM patients who were poor responders to the standard treatment approach (progression free survival < 24 months) to patients who were standard responders (progression free survival > 24 months). Transcriptome sequencing was taken from NDMM patients were obtained from the Multiple Myeloma Research Foundation (MMRF) Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profiles (CoMMpass) study (https://registry.opendata.aws/mmrf-commpass), accessed in February of 2021. We compared NDMM patients with poor (<24 months) and standard (>24 months) treatment responses, identifying differentially expressed RNAs. *************************************************************** Submitter statement concerning raw data: "This data is coming from MMRF CoMMpass study, so it is only accessible through our university collaborators by dbgap access. We only have access to deidentified information and counts for the samples." ***************************************************************